CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01352520
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:36.516198+00:00
Published At: 2026-01-20T00:00:00+00:00
Record Updated At: 2026-01-20
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma", "Lymphoma, Primary Cutaneous Anaplastic Large Cell", "Lymphomatoid Papulosis", "Mycosis Fungoides", "Skin Lymphoma", "Cutaneous Lymphomas", "Lymphoma", "Hematologic Disorder"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-20"
protocolSection.identificationModule.nctId: "NCT01352520"
protocolSection.identificationModule.officialTitle: "Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP)"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.